Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hu3F8 and NK Cells for High-Risk Neuroblastoma
NCT02650648Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2016
- Primary completion
- Jul 2025
- Modality
- Antibody Conjugates, Lymphokine-Activated Killer Cells, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of naxitamab and NK cell therapy (Anhui Provincial Hospital) in neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of patient responses at 2 years. Started Jan 2016; status: completed.
02
Drugs
naxitamabNK cell therapy (Anhui Provincial Hospital)
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02650648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02650648.